{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:47Z","timestamp":1792173527524,"version":"4.4.0"},"reference-count":179,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.vaccine.2016.01.016","type":"journal-article","created":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T05:49:31Z","timestamp":1453355371000},"page":"1152-1161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens"],"prefix":"10.1016","volume":"34","author":[{"given":"Rashmi","family":"Dixit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Herz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Booy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Dec","key":"10.1016\/j.vaccine.2016.01.016_bib0005","first-page":"1113","article-title":"Ueber das zustandekommen der diphtherie-immunit\u00e4t und der tetanus-immunit\u00e4t bei thieren","volume":"49","author":"Von Behring","year":"1890","journal-title":"Deutsche Medicininische Wochenschrift"},{"issue":"Dec (6)","key":"10.1016\/j.vaccine.2016.01.016_bib0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.copbio.2009.10.012","article-title":"Discovery and development of biopharmaceuticals: current issues","volume":"20","author":"Strohl","year":"2009","journal-title":"Curr Opin Biotechnol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0015","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0041-0101(97)00160-8","article-title":"Venoms, antivenoms and immunotherapy","volume":"36","author":"Chippaux","year":"1998","journal-title":"Toxicon"},{"issue":"Mar (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jchromb.2006.07.004","article-title":"Antibody production: polyclonal derived biotherapeutics","volume":"848","author":"Newcombe","year":"2007","journal-title":"J Chromatogr R Analyt Technol Biomed Life Sci"},{"issue":"Oct (8)","key":"10.1016\/j.vaccine.2016.01.016_bib0025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0030","series-title":"Manual on rabies immunoglobulin (RIG) administration [pamphlet]","author":"Association for Prevention & Control of Rabies in India","year":"2009"},{"issue":"Sep (5)","key":"10.1016\/j.vaccine.2016.01.016_bib0035","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.nbt.2011.03.018","article-title":"Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology","volume":"28","author":"Berry","year":"2011","journal-title":"N Biotechnol"},{"issue":"9","key":"10.1016\/j.vaccine.2016.01.016_bib0040","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/nrmicro974","article-title":"Passive antibody therapy for infectious diseases","volume":"2","author":"Casadevall","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"Dec (4)","key":"10.1016\/j.vaccine.2016.01.016_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.idc.2011.07.006","article-title":"Monoclonal antibodies in infectious diseases: clinical pipeline in 2011","volume":"25","author":"TerMeulen","year":"2011","journal-title":"Infect Dis Clin North Am"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.016_bib0050","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0041-0101(02)00393-8","article-title":"Report of a WHO workshop on the standardization and control of antivenoms. Toxicon.41 (5) (pp 541-557), 2003. Date of Publication: 01 May 2003. Standardization and control of antivenoms","volume":"419","author":"Theakston","year":"2003","journal-title":"Toxicon"},{"issue":"Mar (10)","key":"10.1016\/j.vaccine.2016.01.016_bib0055","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1056\/NEJM199503093321004","article-title":"Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragments","volume":"332","author":"Baud","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0060","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1161\/01.CIR.81.6.1744","article-title":"Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study","volume":"81","author":"Antman","year":"1990","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0065","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1081\/CLT-120021116","article-title":"Acute plant poisoning and antitoxin antibodies","volume":"41","author":"Eddleston","year":"2003","journal-title":"J Toxicol Clin Toxicol"},{"issue":"Nov (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0070","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0041-008X(96)80033-0","article-title":"Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab\u2032)2-scorpion venom interactions","volume":"141","author":"P\u00e9pin-Covatta","year":"1996","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0075","first-page":"731","article-title":"Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin","volume":"67","author":"Wilde","year":"1989","journal-title":"Bull World Health Organ"},{"issue":"Apr (15)","key":"10.1016\/j.vaccine.2016.01.016_bib0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJM197604082941501","article-title":"Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies","volume":"294","author":"Smith","year":"1976","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0085","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0041-0101(00)00209-9","article-title":"Comparison between IgG and F(ab\u2032)2 polyvalent antivenoms: neutralization of systemic effects induced by Bothropsasper venom in mice, extravasation of muscle tissue, and potential for induction of adverse reactions","volume":"39","author":"Le\u00f3n","year":"2001","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0090","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0041-0101(96)83667-1","article-title":"Preparation of improved F(ab\u2032)2 antivenoms. An example: new polyvalent anti-European vipers (equine)","volume":"34","author":"Grandgeorge","year":"1996","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0095","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0041-0101(96)00144-4","article-title":"Immunoreactivity of a new generation of horse F(ab\u2032)2 preparations against European viper venoms and the tetanus toxin","volume":"35","author":"P\u00e9pin-Covatta","year":"1997","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0100","series-title":"Production of antirabies serum of equine origin","author":"Luekrajang","year":"2015"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0105","first-page":"119","article-title":"A modification of Jerne's theory of antibody production using the concept of clonal selection","volume":"26","author":"Burnet","year":"1976","journal-title":"CA"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0110","first-page":"249","article-title":"century of antivenom","volume":"35","author":"Lovrecek","year":"2011","journal-title":"Coll Antropol"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0115","series-title":"European pharmacopeoia","first-page":"573","article-title":"Immunosera for human use, animal [monograph on internet]","author":"Council of Europe","year":"2004"},{"issue":"May (3)","key":"10.1016\/j.vaccine.2016.01.016_bib0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.biologicals.2011.02.005","article-title":"Antivenoms for the treatment of snakebite envenomings: the road ahead","volume":"39","author":"Guti\u00e9rreza","year":"2011","journal-title":"Biologicals"},{"issue":"Apr (16)","key":"10.1016\/j.vaccine.2016.01.016_bib0125","first-page":"2446","article-title":"Polyvalent horse F(Ab\u2032)2 snake antivenom: development of process to produce polyvalent horse F(Ab\u2032)2 antibodies anti-African snake venom","volume":"9","author":"Guidlolin","year":"2010","journal-title":"Afr J Biotechnol"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0130","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.toxicon.2009.07.001","article-title":"Epidemiological, clinical and therapeutic aspects of Bothropsasper bites","volume":"54","author":"Otero-Patino","year":"2009","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0135","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0041-0101(98)00220-7","article-title":"A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms","volume":"37","author":"Otero","year":"1999","journal-title":"Toxicon"},{"issue":"Jun (2)","key":"10.1016\/j.vaccine.2016.01.016_bib0140","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1006\/biol.2002.0329","article-title":"Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation","volume":"30","author":"Garc\u00eda","year":"2002","journal-title":"Biologicals"},{"issue":"Sep (3)","key":"10.1016\/j.vaccine.2016.01.016_bib0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.biologicals.2004.07.001","article-title":"Assessment of the viral safety of antivenoms fractionated from equine plasma","volume":"32","author":"Burnouf","year":"2004","journal-title":"Biologicals"},{"issue":"Mar (2)","key":"10.1016\/j.vaccine.2016.01.016_bib0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.biologicals.2011.11.006","article-title":"Low pH formulation of whole IgGantivenom: impact on quality, safety, neutralizing potency and viral inactivation","volume":"40","author":"Solano","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0155","series-title":"WHO guidelines for the production, control and regulation of snake anitvenom immunoglobulins","author":"WHO","year":"2010"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2165\/00003088-200342080-00002","article-title":"Pharmacokinetic-pharmacodynamic relationships of immunoglobulin therapy for envenomation","volume":"42","author":"Guti\u00e9rrez","year":"2003","journal-title":"Clin Pharm"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0165","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0035-9203(98)90802-1","article-title":"Clinical safety of a polyvalent F(ab\u2032)2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. VAO (Venin Afrique de l\u2019Ouest) Investigators","volume":"92","author":"Chippaux","year":"1998","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/15563650.2014.974263","article-title":"Comparison of F(ab\u2032)2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial","volume":"53","author":"Bush","year":"2015","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(24)36597-8","article-title":"Effect of antivenom on venom pharmacokinetics in experimentally envenomed rabbits: toward an optimization of antivenom therapy","volume":"281","author":"Rivi\u00e8re","year":"1997","journal-title":"J Pharm Exp Ther"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0180","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.toxicon.2004.07.032","article-title":"Modelling Tityus scorpion venom and antivenom pharmacokinetics. Evidence of active immunoglobulin G's F(ab\u2032)2 extrusion mechanism from blood to tissues","volume":"44","author":"Sevcik","year":"2004","journal-title":"Toxicon"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0185","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.toxicon.2005.08.010","article-title":"Pharmacokinetics of a F(ab\u2032)2 scorpion antivenom in healthy human volunteers","volume":"46","author":"Vazquez","year":"2005","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0190","first-page":"285","article-title":"Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy","volume":"15","author":"Chippaux","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/toxins6010380","article-title":"Active immunity induced by passive IgG post-exposure protection against ricin","volume":"6","author":"Hu","year":"2014","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0200","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(14)71072-2","article-title":"Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab\u2032)(2) fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study","volume":"15","author":"Bal","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0205","first-page":"CD002153","article-title":"Interventions for preventing reactions to snake antivenom","volume":"2","author":"Nuchpraryoon","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2016.01.016_bib0210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5694\/j.1326-5377.2008.tb01721.x","article-title":"Australian Snakebite Project Investigators. Current use of Australian snake antivenoms and frequency of immediate-type hypersensitivity reactions and anaphylaxis","volume":"188","author":"Isbister","year":"2008","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2796.1997.80896000.x","article-title":"First clinical experiences with specific sheep Fab fragments in snake bite. Report of a multicentre study of Viperaberusenvenoming","volume":"241","author":"Karlson-Stiber","year":"1997","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0041-0101(94)90294-1","article-title":"A comparison of ovine and equine antivenoms","volume":"32","author":"Sj\u00f6str\u00f6m","year":"1994","journal-title":"Toxicon"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4269\/ajtmh.1997.56.291","article-title":"First clinical experiences with a new ovine Fab Echisocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur Serum (Ipser) Africa antivenom","volume":"56","author":"Meyer","year":"1997","journal-title":"Am J Trop Med Hyg"},{"issue":"Dec (7)","key":"10.1016\/j.vaccine.2016.01.016_bib0230","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.toxicon.2006.08.001","article-title":"Twentieth century toxinology and antivenom development in Australia","volume":"48","author":"Winkel","year":"2006","journal-title":"Toxicon"},{"issue":"Dec (7)","key":"10.1016\/j.vaccine.2016.01.016_bib0235","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.toxicon.2009.11.020","article-title":"Snakebite envenoming from a global perspective: towards an integrated approach","volume":"56","author":"Guti\u00e9rrez","year":"2010","journal-title":"Toxicon"},{"issue":"May (6)","key":"10.1016\/j.vaccine.2016.01.016_bib0240","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.toxicon.2006.11.026","article-title":"Antivenomuse, premedication and early adverse reactions in the management of snake bites in rural Papua New Guinea","volume":"49","author":"Williams","year":"2007","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0245","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.humimm.2004.02.029","article-title":"Neonatal Fc receptors discriminates and monitors the pathway of native and modified immunoglobulin G in placental endothelial cells","volume":"65","author":"Radulescu","year":"2004","journal-title":"Hum Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.016_bib0250","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1371\/journal.pntd.0000243","article-title":"Rabies post-exposure prophylaxis in the Philippines: health status of patients having received purified equine F(ab\u2032)2 fragment fabies immunoglobulin (Favirab)","volume":"2","author":"Quiambao","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0255","series-title":"WHO guide for rabies pre and post exposure prophylaxis in humans","author":"WHO","year":"2013"},{"issue":"Nov (51)","key":"10.1016\/j.vaccine.2016.01.016_bib0260","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1016\/j.vaccine.2009.09.036","article-title":"Rabies post-exposure prophylaxis with purified equine rabies immunoglobulin: one-year follow-up of patients with laboratory-confirmed category III rabies exposure in the Philippines","volume":"27","author":"Quiambao","year":"2009","journal-title":"Vaccine"},{"issue":"Mar (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0265","first-page":"31","article-title":"Post-exposure prophylaxis for rabies with ERIG and IDRV in children","volume":"43","author":"Behera","year":"2011","journal-title":"J Commun Dis"},{"issue":"Nov (8570)","key":"10.1016\/j.vaccine.2016.01.016_bib0270","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0140-6736(87)91885-X","article-title":"Safety of equine rabies immune globulin","volume":"330","author":"Wilde","year":"1987","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0275","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.trstmh.2006.04.009","article-title":"Sex- and age-related differences in rabies immunoglobulin hypersensitivity","volume":"101","author":"Suwansrinon","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Jul (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0735-6757(83)90040-2","article-title":"Antivenin therapy in the emergency department","volume":"1","author":"Otten","year":"1983","journal-title":"Am J Emerg Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0285","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0041-0101(85)90025-X","article-title":"Ability of polyvalent (Crotalidae) antivenin to neutralize myonecrosis, hemorrhage and lethality induced by timber rattlesnake (Crotalus horridus horridus) venom","volume":"23","author":"Smith","year":"1985","journal-title":"Toxicon"},{"issue":"12","key":"10.1016\/j.vaccine.2016.01.016_bib0290","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.trstmh.2006.01.006","article-title":"Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothropsasper bites in Colombia","volume":"100","author":"Otero","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Feb (8998)","key":"10.1016\/j.vaccine.2016.01.016_bib0295","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0140-6736(96)90590-5","article-title":"Early infusion of a purified monospecific F(ab\u2032)2 antivenom serum for Bothrops Ianceolatus bites in Martinique","volume":"347","author":"Thomas","year":"1996","journal-title":"Lancet"},{"issue":"Jul (4)","key":"10.1016\/j.vaccine.2016.01.016_bib0300","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1164-6756(98)80004-2","article-title":"Snake (Bothrops lanceolatus) F(ab\u2032)2 antivenom (equine) use in Martinique: safety and efficacy","volume":"7","author":"Thomas","year":"1998","journal-title":"Reanimation Urgences"},{"issue":"Dec (4)","key":"10.1016\/j.vaccine.2016.01.016_bib0305","first-page":"393","article-title":"A controlled clinical trial of a novelantivenom in patients envenomed by Bungarus multicinctus","volume":"6","author":"Ha","year":"2010","journal-title":"J Med Toxicol"},{"issue":"Sep (3)","key":"10.1016\/j.vaccine.2016.01.016_bib0310","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4269\/ajtmh.2007.77.538","article-title":"Investigators of African Antivipmyn in Benin. Clinical trial of an F(ab\u2032)2 polyvalent equine antivenom for African snake bites in Benin","volume":"77","author":"Chippaux","year":"2007","journal-title":"Am J Trop Med Hyg"},{"issue":"May (2)","key":"10.1016\/j.vaccine.2016.01.016_bib0315","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.emc.2004.01.007","article-title":"North American snake envenomation: diagnosis, treatment, and management","volume":"22","author":"Gold","year":"2004","journal-title":"Emerg Med Clin North Am"},{"issue":"Dec (6)","key":"10.1016\/j.vaccine.2016.01.016_bib0320","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.amjsurg.2006.08.056","article-title":"A large single-center experience with treatment of patients with crotalid envenomations: outcomes with and evolution of antivenin therapy","volume":"192","author":"Corneille","year":"2006","journal-title":"Am J Surg"},{"issue":"13","key":"10.1016\/j.vaccine.2016.01.016_bib0325","article-title":"Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review","volume":"9","author":"Lavonas","year":"2009","journal-title":"BMC Emerg Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0330","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.annemergmed.2010.06.550","article-title":"Short-term outcomes after Fab antivenom therapy for severe crotaline snakebite","volume":"57","author":"Lavonas","year":"2011","journal-title":"Ann Emerg Med"},{"issue":"Apr (2)","key":"10.1016\/j.vaccine.2016.01.016_bib0335","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/11207250-000000000-00000","article-title":"Crotalidae polyvalent immune Fab: in patients with North American crotaline envenomation","volume":"25","author":"Keating","year":"2011","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0340","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1197\/j.aem.2006.10.095","article-title":"Safety and efficacy of crotalidae polyvalent immune Fab in pediatric crotaline envenomations","volume":"14","author":"Pizon","year":"2007","journal-title":"Acad Emerg Med"},{"issue":"12","key":"10.1016\/j.vaccine.2016.01.016_bib0345","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/emj.2007.054916","article-title":"Utilisation of crotalidae polyvalent immune fab (ovine) for Viperidae envenomations in children","volume":"25","author":"Johnson","year":"2008","journal-title":"Emerg Med J"},{"issue":"Nov (7475)","key":"10.1016\/j.vaccine.2016.01.016_bib0350","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bmj.329.7475.1129","article-title":"Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms","volume":"329","author":"Smalligan","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0355","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0035-9203(01)90339-6","article-title":"An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii russelii)","volume":"95","author":"Ariaratnam","year":"2001","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0360","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4269\/ajtmh.1997.56.291","article-title":"First clinical experiences with a new ovine Fab Echisocellatus snake bite antivenom in Nigeria: a randomized comparative trial with Institute Pasteur Serum (IPSER) Africa antivenom","volume":"56","author":"Meyer","year":"1997","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0365","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.toxicon.2011.10.008","article-title":"Epidemiology of snakebites in Europe: a systematic review of the literature","volume":"59","author":"Chippaux","year":"2012","journal-title":"Toxicon"},{"issue":"8","key":"10.1016\/j.vaccine.2016.01.016_bib0370","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/qjmed\/hcp081","article-title":"Failure of antivenom to improve recovery in Australian snakebite coagulopathy","volume":"102","author":"Isbister","year":"2009","journal-title":"QJM"},{"issue":"9","key":"10.1016\/j.vaccine.2016.01.016_bib0375","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00134-009-1556-7","article-title":"Clotting factor replacement and recovery from snake venom-induced consumptive coagulopathy","volume":"35","author":"Brown","year":"2009","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0380","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.toxicon.2006.09.007","article-title":"Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: in vivo and in vitro studies","volume":"49","author":"Isbister","year":"2007","journal-title":"Toxicon"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0385","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0196-0644(05)80845-5","article-title":"Snake venom coagulopathy: use and abuse of blood products in the treatment of pit viper envenomation","volume":"20","author":"Burgess","year":"1991","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.016_bib0390","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-199105000-00012","article-title":"Poisonous snakebite in central Texas: possible indicators for antivenin treatment","volume":"213","author":"White","year":"1991","journal-title":"Ann Surg"},{"issue":"Jun (5)","key":"10.1016\/j.vaccine.2016.01.016_bib0395","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1742-1241.2000.tb11912.x","article-title":"Anaphylaxsis and anaphylactoid reactions","volume":"54","author":"Murrant","year":"2000","journal-title":"Int J Clin Pract"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0400","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1553-2712.2001.tb01284.x","article-title":"Epidemiology and hospital course of rattlesnake envenomations cared for at a tertiary referral center in Central Arizona","volume":"8","author":"Tanen","year":"2001","journal-title":"Acad Emerg Med"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0405","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/00005373-198807000-00020","article-title":"Complications of crotalidae antivenin therapy","volume":"28","author":"Jurkovich","year":"1988","journal-title":"J Trauma"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0410","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1580\/1080-6032(2003)14[220:SSFAOA]2.0.CO;2","article-title":"Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation","volume":"14","author":"LoVecchio","year":"2003","journal-title":"Wilderness Environ Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0415","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ewjm.175.2.88","article-title":"Does the aggressive use of polyvalent antivenin for rattlesnake bites result in serious acute side effects?","volume":"175","author":"Offerman","year":"2001","journal-title":"West J Med"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0420","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/j.jpedsurg.2007.11.011","article-title":"Pediatric snakebites: lessons learned from 114 cases","volume":"43","author":"Campbell","year":"2008","journal-title":"J Pediatr Surg"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0425","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1067\/mem.2001.113372","article-title":"Efficacy, safety, and use of snake antivenoms in the United States","volume":"37","author":"Dart","year":"2001","journal-title":"Ann Emerg Med"},{"issue":"Jun (12)","key":"10.1016\/j.vaccine.2016.01.016_bib0430","doi-asserted-by":"crossref","first-page":"698","DOI":"10.5694\/j.1326-5377.1989.tb136764.x","article-title":"An epidemiological and clinical study of snake-bites in childhood","volume":"150","author":"Jamieson","year":"1989","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0435","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/archinte.161.16.2030","article-title":"A randomized multicenter trial of Crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for Crotaline snakebite in the United States","volume":"161","author":"Dart","year":"2001","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0440","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1067\/mem.2002.123134","article-title":"Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom","volume":"39","author":"Clark","year":"2002","journal-title":"Ann Emerg Med"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0445","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1067\/mem.2002.123698","article-title":"Initial postmarketing experience with crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation","volume":"39","author":"Ruha","year":"2002","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.016_bib0450","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/j.1875-9114.2012.01026.x","article-title":"Safety and cost-effectiveness of a clinical protocol implemented to standardize the use of Crotalidae polyvalent immune Fab antivenom at an academic medical centre","volume":"32","author":"Weant","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0455","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1553-2712.2011.01276.x","article-title":"Incidence of immediate hypersensitivity reaction and serum sickness following administration of crotalidae polyvalent immune Fab antivenom: a meta-analysis","volume":"19","author":"Schaeffer","year":"2012","journal-title":"Acad Emerg Med"},{"issue":"Sep (16)","key":"10.1016\/j.vaccine.2016.01.016_bib0460","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/archinte.161.16.2030","article-title":"A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States","volume":"161","author":"Dart","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0465","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0196-0644(97)70107-0","article-title":"Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning","volume":"30","author":"Dart","year":"1997","journal-title":"Ann Emerg Med"},{"issue":"Apr (4)","key":"10.1016\/j.vaccine.2016.01.016_bib0470","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1553-2712.2007.tb02026.x","article-title":"Safety and efficacy of crotalidae polyvalent immune Fab in pediatric crotaline envenomations","volume":"14","author":"Pizon","year":"2007","journal-title":"Acad Emerg Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0475","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1553-2712.2011.01276.x","article-title":"Incidence of immediate hypersensitivity reaction and serum sickness following administration of crotalidae polyvalent immune Fab antivenom: a meta-analysis","volume":"19","author":"Schaeffer","year":"2012","journal-title":"Acad Emerg Med"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0480","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.annemergmed.2007.09.036","article-title":"Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom","volume":"51","author":"Cannon","year":"2008","journal-title":"Ann Emerg Med"},{"issue":"Jan (6512)","key":"10.1016\/j.vaccine.2016.01.016_bib0485","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bmj.292.6512.17","article-title":"Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites","volume":"292","author":"Malasit","year":"1986","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"Jul (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0490","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.toxicon.2004.04.006","article-title":"Evaluation of antivenom therapy in Vipera palaestinae bites","volume":"44","author":"Bentur","year":"2004","journal-title":"Toxicon"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0495","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1371\/journal.pntd.0000767","article-title":"Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echisocellatus) envenoming in Nigeria","volume":"4","author":"Abubakar","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"Dec (8)","key":"10.1016\/j.vaccine.2016.01.016_bib0500","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.toxicon.2011.09.013","article-title":"Clinical effects and treatment of envenoming by Hoplocephalus spp. snakes in Australia: Australian Snakebite Project (ASP-12)","volume":"58","author":"Isbister","year":"2011","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0505","doi-asserted-by":"crossref","first-page":"194","DOI":"10.5694\/mja12.11690","article-title":"Tiger snake (Notechisspp) envenoming: Australian Snakebite Project (ASP-13)","volume":"198","author":"Isbister","year":"2013","journal-title":"Med J Aust"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0510","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2011.11.017","article-title":"Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab\u2032)2] antivenoms, in Bothropsasper bites in Colombia","volume":"59","author":"Otero-Pati\u00f1o","year":"2012","journal-title":"Toxicon"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0515","doi-asserted-by":"crossref","first-page":"e38739","DOI":"10.1371\/journal.pone.0038739","article-title":"A randomised controlled trial of two infusion rates to decrease reactions to antivenom","volume":"7","author":"Isbister","year":"2012","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0520","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/145749690309200211","article-title":"Adder bites. A report of 68 cases","volume":"92","author":"Gr\u00f6nlund","year":"2003","journal-title":"Scand J Surg"},{"issue":"Jun (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0525","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0041-0101(69)90158-5","article-title":"Clinical aspects of snake bite in the Pacific area","volume":"7","author":"Campbell","year":"1969","journal-title":"Toxicon"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.016_bib0530","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1590\/S0036-46651994000500010","article-title":"Snake envenomation in children: early reactions frequency at antivenom in patients pretreated with histamine antagonists HI and H2 and hydrocortisone","volume":"36","author":"Bucarethi","year":"1994","journal-title":"Revista do Instituto de Medicina Tropical de S\u00e3o Paulo"},{"issue":"Nov (35)","key":"10.1016\/j.vaccine.2016.01.016_bib0535","first-page":"1929","article-title":"Evaluation of intravenous immunotherapy with purified F(ab\u2032)2 fragments (Viperfav)","volume":"28","author":"Harry","year":"1999","journal-title":"Presse Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0540","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.actatropica.2007.09.007","article-title":"Low incidence of early reactions to horse-derived F(ab\u2032)(2) antivenom for snakebites in Thailand","volume":"105","author":"Thiansookon","year":"2008","journal-title":"Acta Trop"},{"issue":"Jul (4)","key":"10.1016\/j.vaccine.2016.01.016_bib0545","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/0310057X0903700414","article-title":"Sixteen years of severe Tiger snake (Notechis) envenoming in Perth, Western Australia","volume":"37","author":"Scop","year":"2009","journal-title":"Anaesth Intensive Care"},{"issue":"11","key":"10.1016\/j.vaccine.2016.01.016_bib0550","first-page":"814","article-title":"Severe snakebites in northern KwaZulu-Natal: treatment modalities and outcomes","volume":"99","author":"Wood","year":"2009","journal-title":"S Afr Med J"},{"issue":"11","key":"10.1016\/j.vaccine.2016.01.016_bib0555","doi-asserted-by":"crossref","first-page":"696","DOI":"10.5694\/j.1326-5377.2010.tb04108.x","article-title":"Clinical effects of red-bellied black snake (Pseudechis porphyriacus) envenoming and correlation with venom concentrations: Australian Snakebite Project (ASP-11)","volume":"193","author":"Churchman","year":"2010","journal-title":"Med J Aust"},{"issue":"Aug (3)","key":"10.1016\/j.vaccine.2016.01.016_bib0560","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s13149-012-0223-3","article-title":"clinical study of tolerance and effectiveness of a F(ab\u2032)(2) polyvalent antienom for African snake bites in Kindia, Guinea","volume":"105","author":"Bald\u00e9","year":"2012","journal-title":"Bull Soc Pathol Exot"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0565","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/15563650.2012.660695","article-title":"European viper envenomings: assessment of Viperfav\u2122 and other symptomatic treatments","volume":"50","author":"Boels","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"issue":"12 (4)","key":"10.1016\/j.vaccine.2016.01.016_bib0570","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s13181-010-0051-4","article-title":"A controlled clinical trial of a novel antivenom in patients envenomed by Bungarus multicinctus","volume":"6","author":"Hung","year":"2010","journal-title":"J Med Toxicol"},{"issue":"Dec (6)","key":"10.1016\/j.vaccine.2016.01.016_bib0575","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.4269\/ajtmh.1999.61.1017","article-title":"Short report: treatment of snake envenomations by a new polyvalent antivenom composed of highly purified F(ab)2: results of a clinical trial in northern Cameroon","volume":"61","author":"Chippaux","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"Apr (8)","key":"10.1016\/j.vaccine.2016.01.016_bib0580","doi-asserted-by":"crossref","first-page":"419","DOI":"10.5694\/j.1326-5377.2006.tb00297.x","article-title":"High rate of immediate systemic hypersensitivity reactions to tiger snake antivenom","volume":"184","author":"Isbister","year":"2006","journal-title":"Med J Aust"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0585","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1056\/NEJMoa0808455","article-title":"Antivenom for critically ill children with neurotoxicity from scorpion stings","volume":"360","author":"Boyer","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.vaccine.2016.01.016_bib0590","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/emj.2010.104158","article-title":"Meta-analysis of controlled studies on immunotherapy in severe scorpion envenomation","volume":"28","author":"Abroug","year":"2011","journal-title":"Emerg Med J"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0595","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1081\/CLT-120026514","article-title":"Scorpion envenomations in young children in central Arizona","volume":"41","author":"LoVecchio","year":"2003","journal-title":"J Toxicol Clin Toxicol"},{"issue":"Jan","key":"10.1016\/j.vaccine.2016.01.016_bib0600","doi-asserted-by":"crossref","first-page":"c7136","DOI":"10.1136\/bmj.c7136","article-title":"Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (Mesobuthus tamulus) sting: randomised open label clinical trial","volume":"342","author":"Bawaskar","year":"2011","journal-title":"BMJ"},{"issue":"Apr","key":"10.1016\/j.vaccine.2016.01.016_bib0605","first-page":"283","article-title":"Efficacy of species specific anti-scorpion venom serum (AScVS) against severe, serious scorpion stings (Mesobuthus tamulus concanesisPocock)\u2014an experience from rural hospital in western Maharashtra","volume":"54","author":"Natu","year":"2006","journal-title":"J Assoc Phys India"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0610","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13312-014-0345-8","article-title":"Effectiveness of anti scorpion venom for red scorpion envenomation","volume":"51","author":"Pandurang","year":"2014","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0615","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0924-8579(02)00289-3","article-title":"Treatment of the scorpion envenoming syndrome: 12-years experience with serotherapy","volume":"21","author":"Ismail","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0620","first-page":"273","article-title":"Yes or no for serotherapy in the treatment of scorpion stings and envenomations: a systematic review","volume":"50","author":"Khattabi","year":"2012","journal-title":"Clin Toxicol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0625","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.annemergmed.2005.11.042","article-title":"Lack of scorpion antivenom leads to increased pediatric ICU admissions","volume":"47","author":"Riley","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0630","first-page":"9","article-title":"clinical evaluation of the effectiveness of antivenom in scorpion envenomation","volume":"12","author":"Soomro","year":"2001","journal-title":"Med Forum Mon"},{"issue":"Apr (8)","key":"10.1016\/j.vaccine.2016.01.016_bib0635","doi-asserted-by":"crossref","first-page":"407","DOI":"10.5694\/j.1326-5377.2005.tb06760.x","article-title":"Funnel-web spider bite: a systematic review of recorded clinical cases","volume":"182","author":"Isbister","year":"2005","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.vaccine.2016.01.016_bib0640","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0196-0644(05)81021-2","article-title":"Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases","volume":"21","author":"Clark","year":"1992","journal-title":"Ann Emerg Med"},{"issue":"12","key":"10.1016\/j.vaccine.2016.01.016_bib0645","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1345\/aph.1Q424","article-title":"A US perspective of symptomatic Latrodectus spp. envenomation and treatment: a National Poison Data System review","volume":"45","author":"Monte","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.vaccine.2016.01.016_bib0650","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/15563650.2011.639714","article-title":"Examination of adverse events following black widow antivenom use in California","volume":"50","author":"Nordt","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0655","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.annemergmed.2012.10.008","article-title":"A randomized, double-blind, placebo-controlled trial of a highly purified equine F(ab)2 antibody black widow spider antivenom","volume":"61","author":"Dart","year":"2013","journal-title":"Ann Emerg Med"},{"issue":"12","key":"10.1016\/j.vaccine.2016.01.016_bib0660","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1445-5994.2007.01513.x","article-title":"Safety of i.v. administration of redback spider antivenom","volume":"37","author":"Isbister","year":"2007","journal-title":"Intern Med J"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0665","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0735-1097(10)80170-6","article-title":"Digoxin immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study","volume":"17","author":"Hickey","year":"1991","journal-title":"J Am Coll Cardiol"},{"issue":"Oct (8)","key":"10.1016\/j.vaccine.2016.01.016_bib0670","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1086\/656316","article-title":"Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry","volume":"202","author":"Adisasmito","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0675","series-title":"Clinical management of human infection with avian influenza A (H5N1) virus","author":"WHO","year":"2007"},{"issue":"Feb (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0680","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2174\/18715265112129990006","article-title":"Emergence of oseltamivir resistance: control and management of influenza before, during and after the pandemic","volume":"13","author":"Dixit","year":"2013","journal-title":"Infect Disord Drug Targets"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0685","series-title":"Position paper on collection and use of convalescent plasma or serum as an element in pandemic influenza planning","author":"WHO Blood Regulators Network (BRN)","year":"2009"},{"issue":"May (Suppl 1)","key":"10.1016\/j.vaccine.2016.01.016_bib0690","first-page":"226","article-title":"Logistical feasibility and potential benefits of a population-wide passive immunotherapy program during an influenza pandemic","volume":"5","author":"Wu","year":"2011","journal-title":"Influenza Other Respi Viruses"},{"issue":"October","key":"10.1016\/j.vaccine.2016.01.016_bib0695","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for Influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"issue":"Dec (6)","key":"10.1016\/j.vaccine.2016.01.016_bib0700","first-page":"489","article-title":"Successful treatment of avian influenza with convalescent plasma","volume":"12","author":"Kong","year":"2006","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0705","series-title":"Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO","author":"WHO","year":"2015"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0710","series-title":"Human infection with avian influenza A(H5N1) virus\u2014update","author":"WHO","year":"2014"},{"issue":"10","key":"10.1016\/j.vaccine.2016.01.016_bib0715","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nm1477","article-title":"Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinaemia","volume":"12","author":"de Jong","year":"2006","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.vaccine.2016.01.016_bib0720","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1371\/journal.pmed.0040178","article-title":"Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza","volume":"4","author":"Simmons","year":"2007","journal-title":"PLoS Med"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0725","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2217\/imt.14.40","article-title":"Specific polyclonal F(ab\u2032)2 neutralize a large panel of highly pathogenic avian influenza A viruses (H5N1) and control infection in mice","volume":"6","author":"Herbreteau","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0730","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.intimp.2011.08.011","article-title":"Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab\u2019)2 against highly pathogenic avian influenza H5N1 in mice","volume":"11","author":"Zhao","year":"2011","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0735","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4149\/av_2011_03_261","article-title":"Evaluation of anti-influenza efficiency of polyclonal IgG antibodies specific to the ectodomain of M2 protein of influenza A virus by passive immunization of mice","volume":"55","author":"Kir\u00e1ly","year":"2011","journal-title":"Acta Virol"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0740","series-title":"Influenza at the human-animal interface","author":"WHO","year":"2015"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0745","doi-asserted-by":"crossref","first-page":"f4752","DOI":"10.1136\/bmj.f4752","article-title":"Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation","volume":"347","author":"Qi","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0750","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa044021","article-title":"Probable person-to-person transmission of avian influenza A (H5N1)","volume":"352","author":"Ungchusak","year":"2005","journal-title":"N Engl J Med"},{"issue":"Apr (9622)","key":"10.1016\/j.vaccine.2016.01.016_bib0755","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(08)60493-6","article-title":"Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China","volume":"371","author":"Wang","year":"2008","journal-title":"Lancet"},{"issue":"Dec (10)","key":"10.1016\/j.vaccine.2016.01.016_bib0760","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2213-2600(13)70221-2","article-title":"Human infection with avian influenza A H6N1 virus: an epidemiological analysis","volume":"1","author":"Wei","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0765","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jinf.2013.12.014","article-title":"Emergence in China of human disease due to avian influenza A(H10N8)\u2014cause for concern?","volume":"68","author":"To","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0770","series-title":"Avian influenza A (H10N8). Factsheet","author":"WHO","year":"2014"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0775","series-title":"China records new H10N8 bird flu death","author":"The Malaysian Insider","year":"2014"},{"issue":"10","key":"10.1016\/j.vaccine.2016.01.016_bib0780","doi-asserted-by":"crossref","first-page":"e13622","DOI":"10.1371\/journal.pone.0013622","article-title":"Prevention and treatment of influenza with hyperimmune bovine colostrum antibody","volume":"5","author":"Ng","year":"2010","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.vaccine.2016.01.016_bib0785","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/milmed\/168.3.246","article-title":"Compared protective effect of nasal immunoprophylaxis using a new human monoclonal IgM antibody, human polyclonal antibodies, F(ab\u2032)2, amantadine, and zanamivir for prophylaxis of influenza A virus pneumonia in mice","volume":"168","author":"Hernandez","year":"2003","journal-title":"Mil Med"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0790","doi-asserted-by":"crossref","first-page":"e89674","DOI":"10.1371\/journal.pone.0089674","article-title":"Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis","volume":"9","author":"Rinaldi","year":"2014","journal-title":"PLoS ONE"},{"issue":"9885","key":"10.1016\/j.vaccine.2016.01.016_bib0795","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/S0140-6736(13)60982-4","article-title":"Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: a report of nosocomial transmission","volume":"381","author":"Guery","year":"2013","journal-title":"Lancet"},{"issue":"Sep (38)","key":"10.1016\/j.vaccine.2016.01.016_bib0800","first-page":"793","article-title":"Updated information on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection and guidance for the public, clinicians, and public health authorities, 2012\u20132013","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0805","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV)\u2014Republic of Korea","author":"Disease Outbreak News","year":"2015","journal-title":"Disease Outbreak News"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0810","unstructured":"\u3008http:\/\/apps.who.int\/iris\/bitstream\/10665\/179184\/2\/WHO_MERS_RA_15.1_eng.pdf\u3009 (accessed 25 July 2015)"},{"issue":"Dec (9909)","key":"10.1016\/j.vaccine.2016.01.016_bib0815","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(13)61887-5","article-title":"Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study","volume":"382","author":"Cotten","year":"2013","journal-title":"Lancet"},{"issue":"Dec (9909)","key":"10.1016\/j.vaccine.2016.01.016_bib0820","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(13)61955-8","article-title":"Tracking the transmission and evolution of MERS-CoV","volume":"382","author":"Hui","year":"2013","journal-title":"Lancet"},{"issue":"Jun (11)","key":"10.1016\/j.vaccine.2016.01.016_bib0825","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1128\/JVI.00446-15","article-title":"Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection","volume":"89","author":"Zhao","year":"2015","journal-title":"J Virol"},{"issue":"November","key":"10.1016\/j.vaccine.2016.01.016_bib0830","article-title":"Estimating potential incidence of MERS-CoV associated with Hajj Pilgrims to Saudi Arabia, 2014","author":"Lessler","year":"2014","journal-title":"PLoS Curr"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0835","unstructured":"Ebola Situation Report\u201422 July 2015 \u3008http:\/\/apps.who.int\/ebola\/current-situation\/ebola-situation-report-22-july-2015\u3009 (accessed 25 July 2015)."},{"issue":"Jan (2)","key":"10.1016\/j.vaccine.2016.01.016_bib0840","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/JVI.78.2.834-840.2004","article-title":"Nipah virus: vaccination and passive protection studies in a hamster model","volume":"78","author":"Guillaume","year":"2004","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2016.01.016_bib0845","doi-asserted-by":"crossref","first-page":"e35996","DOI":"10.1371\/journal.pone.0035996","article-title":"DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)","volume":"7","author":"Brocato","year":"2012","journal-title":"PLoS ONE"},{"issue":"Mar (13)","key":"10.1016\/j.vaccine.2016.01.016_bib0850","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1073\/pnas.1200409109","article-title":"Postexposure antibody prophylaxis protects nonhuman primates from filovirusdisease","volume":"109","author":"Dye","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"May (10)","key":"10.1016\/j.vaccine.2016.01.016_bib0855","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.75.10.4649-4654.2001","article-title":"Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication","volume":"75","author":"Gupta","year":"2001","journal-title":"J Virol"},{"issue":"Feb (Suppl. 1)","key":"10.1016\/j.vaccine.2016.01.016_bib0860","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/514310","article-title":"Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebola virus infections","volume":"179","author":"Jahrling","year":"1999","journal-title":"J Infect Dis"},{"issue":"Feb (Suppl 1)","key":"10.1016\/j.vaccine.2016.01.016_bib0865","doi-asserted-by":"crossref","first-page":"S218","DOI":"10.1086\/514294","article-title":"Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections","volume":"179","author":"Kudoyarova-Zubavichene","year":"1999","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2016.01.016_bib0870","first-page":"270","article-title":"Development and study of the properties of immunoglobulin against Ebola fever","volume":"40","author":"Borisevich","year":"1995","journal-title":"Vopr Virusol"},{"issue":"2","key":"10.1016\/j.vaccine.2016.01.016_bib0875","first-page":"82","article-title":"The evaluation in hamadryas baboons of the possibility for the specific prevention of Ebola fever","volume":"39","author":"Mikha\u012dlov","year":"1994","journal-title":"Vopr Virusol"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0880","first-page":"135","article-title":"Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses","volume":"11","author":"Jahrling","year":"1996","journal-title":"Arch Virol Suppl"},{"key":"10.1016\/j.vaccine.2016.01.016_bib0885","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.intimp.2006.10.009","article-title":"Inhibition of infection caused by severe respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice","volume":"7","author":"Zhou","year":"2007","journal-title":"Int Immunopharmacol"},{"issue":"Spring (1)","key":"10.1016\/j.vaccine.2016.01.016_bib0890","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1089\/vim.2006.0064","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters","volume":"20","author":"Zhao","year":"2007","journal-title":"Viral Immunol"},{"issue":"Sep (3)","key":"10.1016\/j.vaccine.2016.01.016_bib0895","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1089\/vim.2007.0038","article-title":"Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab\u2019)2","volume":"20","author":"Luo","year":"2007","journal-title":"Viral Immunol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T05:42:16Z","timestamp":1748756536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":179,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0264410X16000426"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown copyright \u00a9 2016 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}